Latent Autoimmune Diabetes in Adults (LADA) in Recent Clinical Practice
Diabetic patients have been increasing and this tendency has
become a medical and social problem worldwide.
There are some types of diabetes, in which the prevalence of type 2 diabetesmellitus
has been higher without requiring insulin treatment. On the other hand, type 1 diabetes mellitus has
acute onset due to virus infection.
Under such circumstances, there is a disease that has been clinically important in recent years. It is
Latent autoimmune diabetes in adults.
As to LADA, there are both clinical and immunological characteristics between T2DM and T1DM.
The genesis of T1DM has been the autoimmune destruction of islet β-cells in the pancreas.
There are some major anti-islet autoantibodies, such as glutamic
acid decarboxylase autoantibody, and T1DM shows a
high prevalence of GADA ADA.
The characteristic point of LADA would be a conceptual
phenotype that exists between conventional T1DM and T2DM.
Recently, there has been some clinical issues and challenges for LADA.
They include the prevention of progressive β-cell failure
by dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 analogs, metformin, and insulin.
Furthermore, there was an investigation of islet cells and exocrine pancreatic
tissues in the pancreas for LADA.
Diabetes Res Open J. 2019; 5(1): e4-e6. doi: 10.17140/DROJ-5-e014